Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma

 

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone for Relapsed-and-Refractory Multiple Myeloma (9056)
A Phase 1b/2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma (ACE-MM-102)

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01997840

SAR650984 for CD38+ Hematological Malignancies
Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: William Bensinger, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252

ACY-1215 in Combination With Lenalidomide, and Dexamethasone for Multiple Myeloma
A Phase 1, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01583283

MK-3475 for Hematologic Malignancies
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies

Investigator: William I. Bensinger, MD;   Conditions: Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma;    Status: Pending;   Study ID: NCT01953692

GSK2857916 for Relapsed/Refractory Multiple Myeloma (20142069)
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Investigator: Edward Libby;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02064387